Berberis aristata/Silybum marianum fixed combination (Berberol®) effects on lipid profile in dyslipidemic patients intolerant to statins at high dosages: A randomized, placebo-controlled, clinical trial

Phytomedicine

Volumn 22, Issue 2, 2015, Pages 231-237

  Derosa, Giuseppe ^a   Romano, Davide ^a   D'Angelo, Angela ^a   Maffioli, Pamela ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Berberis aristata and Silybum marianum Dyslipidemia Lipid profile Myalgia Statins

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTILIPEMIC AGENT; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; BERBEROL; CREATINE KINASE; DRUG ADMINISTRATION; DRUG THERAPY; GLUCOSE; GLUCOSE BLOOD LEVEL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; MYELOPEROXIDASE; NUTRACEUTICAL; PLACEBO; PLANT EXTRACT; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BERBERIS; BERBERIS ARISTATA; BLOOD; CHEMISTRY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG THERAPY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSLIPIDEMIAS; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; METABOLISM; MIDDLE AGED; MYALGIA; MYOPATHY; PATIENT COMPLIANCE; PHYTOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; SILYBUM MARIANUM; TABLET; TRIACYLGLYCEROL BLOOD LEVEL;

ADMINISTRATION AND DOSAGE; ADULT; AGED; BERBERIS; BLOOD; BLOOD GLUCOSE; CHEMISTRY; DOUBLE-BLIND METHOD; DRUG THERAPY; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; METABOLISM; MIDDLE AGED; MILK THISTLE; PHYTOTHERAPY; PLANT EXTRACTS; THERAPEUTIC USE;

BERBERIS; BERBERIS ARISTATA; SILYBUM MARIANUM;

EID: 84964290923     PISSN: 09447113     EISSN: 1618095X     Source Type: Journal    
DOI: 10.1016/j.phymed.2014.11.018     Document Type: Article

References (43)

1. Brown A.S. Use of combination therapy for dyslipidemia: a lipid clinic approach Am. J. Cardiol. 90 2002 44K 49K
2. Brusq J.M., Ancellin N., Grondin P., Guillard R., Martin S. et al. Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine J. Lipid Res. 47 2006 1281 1288
3. Chen J., Zhu H., Chu V.M., Jang Y.S., Son J.Y. et al. Quality control of a herbal medicinal preparation using high-performance liquid chromatographic and capillary electrophoretic methods J. Pharm. Biomed. Anal. 55 2011 206 210
4. Cicero A.F., Minardi M., Mirembe S., Pedro E., Gaddi A. Effects of a new low dose soy protein/beta-sitosterol association on plasma lipid levels and oxidation Eur. J. Nutr. 43 2004 319 322
5. Cicero A.F.G., Ertek S. Natural sources of antidyslipidemic agents: is there an evidence-based approach for their prescription? Mediterr. J. Nutr. Metab. 1 2008 85 93
6. Cicero A.F., Ferroni A., Ertek S. Tolerability and safety of commonly used dietary supplements and nutraceuticals with lipid-lowering effects Expert Opin. Drug Saf. 11 2012 753 766
7. Cicero A.F., Derosa G., Parini A., Maffioli P., D'Addato S. et al. Red yeast rice improves lipid pattern, high-sensitivity C-reactive protein, and vascular remodeling parameters in moderately hypercholesterolemic Italian subjects Nutr. Res. 33 2013 622 628
8. Davidson M.H. Combination therapy for dyslipidemia: safety and regulatory considerations Am. J. Cardiol. 90 2002 50K 60K
9. Derosa G., Cicero A.F.G., Fogari E., D'Angelo A., Bonaventura A. et al. Effects of n-3 PUFAs on insulin resistance after an oral fat load Eur. J. Lipid. Sci. Technol. 113 2011 950 960
10. Derosa G., Cicero A.F., Fogari E., D'Angelo A., Bonaventura A. et al. n-3 PUFAs effects on post-prandial variation of metalloproteinases, inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load J. Clin. Lipidol. 6 2012 553 564
11. Derosa G., Maffioli P., Cicero A.F. Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials Expert Opin. Biol. Ther. 12 2012 1113 1124
12. Derosa G., D'Angelo A., Mugellini A., Pesce R.M., Fogari E., Maffioli P. Evaluation of emerging biomarkers in cardiovascular risk stratification of hypertensive patients: a 2-year study Curr. Med. Res. Opin. 28 2012 1435 1445
13. Derosa G., D'Angelo A., Bonaventura A., Bianchi L., Romano D. et al. Effects of berberine on lipid profile in subjects with low cardiovascular risk Expert Opin. Biol. Ther. 13 2013 475 482
14. Derosa G., Bonaventura A., Bianchi L., Romano D., D'Angelo A. et al. Effects of Berberis aristata/Silybum marianum association on metabolic parameters and adipocytokines in overweight dyslipidemic patients J. Biol. Regul. Homeostatic Agents 27 2013 709 720
15. Derosa G., Bonaventura A., Bianchi L., Romano D., D'Angelo A. et al. Berberis aristata/Silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients Expert Opin. Biol. Ther. 13 2013 1495 1506
16. European Diabetes Policy Group A desktop guide to type 2 diabetes mellitus Diabetic Med. 16 1999 716 730
17. European Pharmacopoeia 6.0, Milk Thistle Dry Extract, Refined and Standardized, pp. 2426-2427
18. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III) J. Am. Med. Assoc. 285 2001 2486 2497
19. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge Clin. Chem. 18 1972 499 502
20. Guidelines Subcommittee World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension J. Hypertens. 17 1999 151 183
21. Havel R.J., Eder H.A., Bragdon J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum J. Clin. Invest. 34 1955 1345 1353
22. Heding L.G. Determination of total serum insulin (IRI) in insulin-treated diabetic patients Diabetologia 8 1972 260 266
23. Huseini H.F., Larijani B., Heshmat R., Fakhrzadeh H., Radjabipour B. et al. The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial Phytother. Res. 20 2006 1036 1039
24. Kidd P., Head K. A review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos) Altern. Med. Rev. 10 2005 193 203
25. Klose S., Borner K. Enzymatische Bestimmung des Gesamtcholesterins mit dem [Enzymatic dosage of total cholesterolemia by Greiner Selective Analyzer (GSA II)] J. Clin. Chem. Clin. Biochem. 15 1978 121 130
26. Kong W., Wei J., Abidi P., Lin M., Inaba S. et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins Nat. Med. 10 2004 1344 1351
27. Kong W.J., Wei J., Zuo Z.Y., Wang Y.M., Song D.Q. et al. Combination of simvastatin with berberine improves the lipid-lowering efficacy Metabolism 57 2008 1029 1037
28. Luper S. A review of plants used in the treatment of liver disease: part 1 Altern. Med. Rev. 3 1998 410 421
29. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 28 1985 412 419
30. McClure D.L., Valuck R.J., Glanz M., Hokanson J.E. Systematic review and meta-analysis of clinically relevant adverse events from HMG CoA reductase inhibitor trials worldwide from 1982 to present Pharmacoepidemiol. Drug Saf. 16 2007 132
31. Morishita K., Kubota N., Asano S., Kaziro Y., Nagata S. Molecular cloning and characterization of cDNA for human myeloperoxidase J. Biol. Chem. 262 1987 3844 3851
32. Natarajan P., Ray K.K., Cannon C.P. High density lipoprotein and coronary heart disease: current and future therapies J. Am. Coll. Cardiol. 55 2010 1283 1299
33. NCEP Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 4216
34. Rifai N., Tracy R.P., Ridker P.M. Clinical efficacy of an automated high-sensitivity C-reactive protein assay Clin. Chem. 45 1999 2136 2141
35. Sobolová L., Skottová N., Vecera R., Urbánek K. Effect of silymarin and its polyphenolic fraction on cholesterol absorption in rats Pharmacol. Res. 53 2006 104 112
36. The Council for International Organisation of Medical Sciences Proposed International Guidelines for Biomedical Research Involving Human Subjects 1982 WHO Geneva
37. Vijan S., Hayward R.A. American College of Physicians Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians Ann. Intern. Med. 140 2004 650 658
38. Wahlefeld A.W. Triglycerides determination after enzymatic hydrolysis Bergmeyer H.U. Methods of Enzymatic Analysis second English ed. 1974 Academic Press New York, USA 18 31
39. Wallace T.M., Levy J.C., Matthews D.R. Use and abuse of HOMA modeling Diabetes Care 27 2004 1487 1495
40. Weber H.A., Zart M.K., Hodges A.E., White K.D., Barnes S.M. et al. Method validation for determination of alkaloid content in goldenseal root powder J. AOAC Int. 86 2003 476 483
41. Winer B.J. Statistical Principles in Experimental Design second ed. 1971 McGraw-Hill New York, USA
42. World Health Organization Obesity: preventing and managing the global epidemic Report of WHO Consultation on Obesity 1997 WHO Geneva
43. Zhou S., Lim L.Y., Chowbay B. Herbal modulation of P-glycoprotein Drug. Metab. Rev. 36 2004 57 104